Nolte M T, Pirofsky B, Gerritz G A, Golding B
Clin Exp Immunol. 1979 May;36(2):237-43.
Twenty patients with antibody deficiency were treated at random with either intramuscular immune serum globulin (ISG) or intravenous modified immune serum globulin (M-ISG). Fourteen patients received of 259 M-ISG infusions during 242 months of treatment. Catastrophic vasomotor reactions were not observed. A single dose of 150 mg/kilo M-ISG increased serum IgG values a mean 248 mg%. Intravenous M-ISG therapy was effective in reducing the incidence of acute infections. Subjects receiving M-ISG developed 0.103 acute infections per month of treatment. Patients injected with ISG had 0.295 acute infections per month of treatment. Seven subjects had separate courses of both intravenous M-ISG and intramuscular ISG. Acute infections per month of treatment for M-ISG and ISG were 0.104 and 0.406, respectively.
20名抗体缺乏患者被随机分为两组，分别接受肌肉注射免疫血清球蛋白（ISG）或静脉注射改良免疫血清球蛋白（M-ISG）治疗。在242个月的治疗期间，14名患者接受了259次M-ISG输注。未观察到严重的血管舒缩反应。单剂量150mg/kg的M-ISG可使血清IgG值平均升高248mg%。静脉注射M-ISG疗法可有效降低急性感染的发生率。接受M-ISG治疗的受试者在每月治疗期间发生0.103次急性感染。注射ISG的患者每月治疗期间发生0.295次急性感染。7名受试者分别接受了静脉注射M-ISG和肌肉注射ISG的疗程。M-ISG和ISG每月治疗期间的急性感染发生率分别为0.104和0.406。
